Massachusetts Institute of Technology

Albert Einstein College of Medicine

Ifo-regina Elena Cancer Institute

Cornell University

King's College London

Montefiore Medical Center

Frank B Gertler

John S Condeelis

Douglas A Lauffenburger

Madeleine J Oudin

Sumanta Goswami

Jason Neil

Paola Nisticò

Forest White

Linda G Griffith

Maja H Oktay

Thomas Rohan

Miles Aaron Miller

Christopher Boyce Burge

Matthias Krause

Upamali Perera

Joan G Jones

Shannon K Hughes-Alford

Jurgen Wehland

Joseph J Loureiro

James E Bear

Aaron Samuel Meyer

Shannon K Hughes

Irina M Shapiro

Guillaume Carmona

Wu Albert Cheng

Paola Nistico

Methods and compositions are provided for diagnosing or inhibiting invasion or metastasis of a cancer in a subject based on Mena.

Methods involving Menain screening for inhibitors of cancer invasion and metastasis

Cancer invasion is a hallmark of metastasis. The mesenchymal mode of cancer cell invasion is mediated by elongated membrane protrusions driven by the assembly of branched F-actin networks. Described herein are compositions and methods for assessing and treating a subject having metastatic cancer or at risk of developing metastatic cancer, e.g., metastatic breast cancer, through the determination of Lamellipodin protein or gene expression levels in the subject.

Methods for identifying and treating invasive/metastatic breast cancers

[object Object]

Methods, compounds and kits relating to treating cancer, reducing kinase inhibitor or resistance, and reducing or preventing diminished ectodomain shedding are described.

Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors

The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.

Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer

Methods and kits for diagnosis, prognosis and treatment of metastatic tumors are provided where the metastatic tumor is characterized by changes in expression of +++, ++ and/or 11a variants of Mena.

Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors

Disclosed are methods for determining the risk of tumor cells undergoing metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, and for determining a course of treatment for a localized tumor comprising detecting the presence of an endothelial cell, a macrophage, and an invasive tumor cell in direct apposition in a tumor sample from a subject.

Tumor microenvironment of metastasis (TMEM) and uses thereof in diagnosis, prognosis and treatment of tumors

Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors

The invention relates to methods for regulating cell motility and related products. In particular methods for promoting and preventing cell migration are described herein. The methods have a variety of clinical, diagnostic and therapeutic uses, e.g., for wound healing, tissue generation, and treatment and prevention of neurodegenerative disease and metastasis.

Methods and products for regulating cell motility

Growing community of inventors

Boston, MA, United States of America

Frank B Gertler